University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Items where Author is "Kottke, T"

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 25.

Article

Kottke, Tim, Evgin, Laura, Shim, Kevin G., Rommelfanger, Diana, Boisgerault, Nicolas, Zaidi, Shane, Diaz, Rosa Maria, Thompson, Jill, Ilett, Elizabeth, Coffey, Matt, Selby, Peter, Pandha, Hardev, Harrington, Kevin, Melcher, Alan and Vile, Richard (2017) Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence Cancer Immunology Research, 5 (11). pp. 1029-1045.

Rajani, K, Parrish, C, Kottke, T, Thompson, J, Zaidi, S, Ilett, L, Shim, KG, Diaz, R-M, Pandha, H, Harrington, K, Coffey, M, Melcher, A and Vile, R (2016) Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses MOLECULAR THERAPY, 24 (1). pp. 166-174.

Zaidi, S, Blanchard, M, Shim, K, Ilett, E, Rajani, K, Parrish, C, Boisgerault, N, Kottke, T, Thompson, J, Celis, E, Pulido, J, Selby, P, Pandha, H, Melcher, A, Harrington, K and Vile, R (2015) Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine melanoma Model After Treatment With Immunomodulatory Agents MOLECULAR THERAPY, 23 (5). pp. 845-856.

Alonso-Camino, V, Rajani, K, Kottke, T, Rommelfanger-Konkol, D, Zaidi, S, Thompson, J, Pulido, J, Ilett, E, Donnelly, O, Selby, P, Pandha, H, Melcher, A, Harrington, K, Diaz, RM and Vile, R (2014) The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site MOLECULAR THERAPY, 22 (11). pp. 1936-1948.

Ilett, E, Kottke, T, Donnelly, O, Thompson, J, Willmon, C, Diaz, R, Zaidi, S, Coffey, M, Selby, P, Harrington, K, Pandha, H, Melcher, A and Vile, R (2014) Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus MOLECULAR THERAPY, 22 (10). pp. 1851-1863.

Kottke, T, Boisgerault, N, Diaz, RM, Donnelly, O, Rommelfanger-Konkol, D, Pulido, J, Thompson, J, Mukhopadhyay, D, Kaspar, R, Coffey, M, Pandha, H, Melcher, A, Harrington, K, Selby, P and Vile, R (2013) Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence NATURE MEDICINE, 19 (12). pp. 1625-1631.

Boisgerault, N, Kottke, T, Pulido, J, Thompson, J, Diaz, RM, Rommelfanger-Konkol, D, Embry, A, Saenz, D, Poeschla, E, Pandha, H, Harrington, K, Melcher, A, Selby, P and Vile, R (2013) Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse MOLECULAR THERAPY, 21 (8). pp. 1507-1516.

Pulido, J, Kottke, T, Thompson, J, Galivo, F, Wongthida, P, Diaz, RM, Rommelfanger, D, Ilett, E, Pease, L, Pandha, H, Harrington, K, Selby, P, Melcher, A and Vile, R (2012) Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma Nature Biotechnology, 30 (4). pp. 337-343.

Kottke, T, Chester, J, Ilett, E, Thompson, J, Diaz, R, Coffey, M, Selby, P, Nuovo, G, Pulido, J and Mukhopadhyay, D (2011) Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther, 19 (10). pp. 1802-1812.

Kottke, T, Errington, F, Pulido, J, Galivo, F, Thompson, J, Wongthida, P, Diaz, RM, Chong, H, Ilett, E, Chester, J, Pandha, H, Harrington, K, Selby, P, Melcher, A and Vile, R (2011) Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med, 17 (7). pp. 854-859.

Heinemann, L, Simpson, GR, Boxall, A, Kottke, T, Relph, KL, Vile, R, Melcher, A, Prestwich, R, Harrington, KJ, Morgan, R and Pandha, HS (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer, 11.

Kottke, T, Hall, G, Pulido, J, Diaz, RM, Thompson, J, Chong, H, Selby, P, Coffey, M, Pandha, H, Chester, J, Melcher, A, Harrington, K and Vile, R (2010) Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice JOURNAL OF CLINICAL INVESTIGATION, 120 (5). pp. 1551-1560.

Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T, Thompson, J, Galivo, F, Harrington, KJ, Pandha, HS, Selby, PJ, Vile, RG and Melcher, AA (2009) Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication CLINICAL CANCER RESEARCH, 15 (13). pp. 4374-4381.

Ilett, EJ, Prestwich, RJ, Kottke, T, Errington, F, Thompson, JM, Harrington, KJ, Pandha, HS, Coffey, M, Selby, PJ, Vile, RG and Melcher, AA (2009) Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity GENE THERAPY, 16 (5). pp. 689-699.

Prestwich, RJ, Errington, F, Ilett, EJ, Morgan, RSM, Scott, KJ, Kottke, T, Thompson, J, Morrison, EE, Harrington, KJ, Pandha, HS, Selby, PJ, Vile, RG and Melcher, AA (2008) Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity CLINICAL CANCER RESEARCH, 14 (22). pp. 7358-7366.

Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM, Thompson, J, Selby, P, de Bono, J, Melcher, A, Pandha, H, Coffey, M, Vile, R and Harrington, K (2008) Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus CLINICAL CANCER RESEARCH, 14 (1). pp. 259-269.

Conference or Workshop Item

Rajani, K, Shim, K, Parrish, C, Ilett, L, Kottke, T, Pulido, J, Thompson, J, Pandha, H, Harrington, K, Melcher, A, Errington, F, Diaz, R, Coffey, M, Zaidi, S and Vile, R (2015) Combination Therapy of Reovirus and PD-1 Blockade Effectively Establishes Tumor Control Via Innate and Adaptive Immune Responses In: 18th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2015-05-13 - 2015-05-16, New Orleans, LA.

Zaidi, S, Blanchard, M, Shim, K, Ilett, E, Kottke, T, Thompson, J, Celis, E, Pandha, H, Selby, P, Melcher, A, Harrington, K and Vile, R (2014) Acquisition of Mutated BRAF Is as a Major Effector of Melanoma Recurrence Which Can Be Targeted By Immuno- or Chemo-Therapy In: 17th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2014-05-21 - 2014-05-24, Washington, DC.

Ilett, E, Kottke, T, Donnelly, O, Thompson, J, Willmon, C, Diaz, R, Zaidi, S, Coffey, M, Selby, P, Harrington, K, Pandha, H, Melcher, A and Vile, R (2014) Direct, Cytokine-Conditioned, In Vivo Cell Loading for Systemic Delivery of Oncolytic Viruses In: 17th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2014-05-21 - 2014-05-24, Washington, DC.

Alonso-Camino, V, Rajani, K, Kottke, T, Rommelfanger-Konkol, D, Zaidi, S, Thompson, J, Pulido, J, Ilett, L, Selby, P, Pandha, H, Melcher, A, Harrington, K, Diaz, R and Vile, R (2014) The Profile of Tumor Antigens Which Can Be Targeted By Immunotherapy Depends Upon the Tumor's Anatomical Site In: 17th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2014-05-21 - 2014-05-24, Washington, DC.

Kottke, T, Donnelly, O, Ilett, E, Thompson, J, Diaz, R, Coffey, M, Selby, P, Pandha, H, Harrington, K, Melcher, A and Vile, R (2013) In Vivo Expansion of a Recipient Population of Cell Carriers Allows for Highly Effective Systemic Delivery of Oncolytic Reovirus Even in the Presence of Neutralizing Antibody In: 16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2013-05-15 - 2013-05-18, Salt Lake City, UT.

Boisgerault, N, Pulido, J, Kottke, T, Donnelly, O, Celis, E, Thompson, J, Diaz, R, Harrington, K, Pandha, H, Selby, P, Melcher, A and Vile, R (2013) Tumor Recurrences Share Immunogenic Antigens across Both Tumor Types and Primary Treatments Which Can Be Therapeutically Targeted with VSV-cDNA Libraries In: 16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2013-05-15 - 2013-05-18, Salt Lake City, UT.

Kottke, T, Donnelly, O, Boisgerault, N, Diaz, R, Rommelfanger-Konkol, D, Pulido, J, Thompson, J, Mukhopadhyay, D, Knutson, K, Behrens, M, Kaspar, R, Coffey, M, Selby, P, Harrington, K, Melcher, A, Pandha, H and Vile, R (2013) Tumor Relapse Is Associated with an Innate Immune Resistant Phenotype across Tumor and Treatment Types Which Can Be Targeted with Rational Second Line Therapies In: 16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2013-05-15 - 2013-05-18, Salt Lake City, UT.

Kottke, T, Donnelly, O, Boisgerault, N, Diaz, R, Thompson, J, Chester, J, Pandha, H, Harrington, K, Melcher, A and Vile, R (2012) Characterization of the Mechanisms of Tumor Dormancy and Recurrence Following Front Line Immuno-, Viro- or Suicide Gene-, Therapy In: 15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), 2012-05-16 - 2012-05-19, Philadelphia, PA.

Heinemann, L, Kottke, T, Vile, R, Coffey, MC, Harrington, K, Melcher, A and Pandha, HS (2008) Synergistic Anti-Tumor Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model In: 23rd Annual Scientific Meeting of the International-Society-for-Biological-Therapy-of-Cancer, 2008-10-31 - 2008-11-02, San Diego, CA.

This list was generated on Sun Nov 19 08:55:14 2017 UTC.

Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800